Cenra Inc.

TWSE:1701 Voorraadrapport

Marktkapitalisatie: NT$6.0b

Cenra Inkomsten in het verleden

Verleden criteriumcontroles 1/6

Cenra's earnings have been declining at an average annual rate of -3.3%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been growing at an average rate of 2.4% per year. Cenra's return on equity is 4.8%, and it has net margins of 4%.

Belangrijke informatie

-3.3%

Groei van de winst

-3.3%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie18.5%
Inkomstengroei2.4%
Rendement op eigen vermogen4.8%
Nettomarge4.0%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

China Chemical & Pharmaceutical's (TWSE:1701) Dividend Will Be Reduced To NT$0.50

Jul 12
China Chemical & Pharmaceutical's (TWSE:1701) Dividend Will Be Reduced To NT$0.50

Here's Why We Think China Chemical & Pharmaceutical (TPE:1701) Is Well Worth Watching

Apr 25
Here's Why We Think China Chemical & Pharmaceutical (TPE:1701) Is Well Worth Watching

We Think China Chemical & Pharmaceutical (TPE:1701) Can Stay On Top Of Its Debt

Apr 07
We Think China Chemical & Pharmaceutical (TPE:1701) Can Stay On Top Of Its Debt

The China Chemical & Pharmaceutical (TPE:1701) Share Price Is Up 34% And Shareholders Are Holding On

Mar 17
The China Chemical & Pharmaceutical (TPE:1701) Share Price Is Up 34% And Shareholders Are Holding On

China Chemical & Pharmaceutical Co., Ltd.'s (TPE:1701) Stock Has Shown A Decent Performance: Have Financials A Role To Play?

Feb 24
China Chemical & Pharmaceutical Co., Ltd.'s (TPE:1701) Stock Has Shown A Decent Performance: Have Financials A Role To Play?

Is China Chemical & Pharmaceutical Co., Ltd. (TPE:1701) A Good Fit For Your Dividend Portfolio?

Jan 27
Is China Chemical & Pharmaceutical Co., Ltd. (TPE:1701) A Good Fit For Your Dividend Portfolio?

Does China Chemical & Pharmaceutical (TPE:1701) Have A Healthy Balance Sheet?

Jan 06
Does China Chemical & Pharmaceutical (TPE:1701) Have A Healthy Balance Sheet?

The China Chemical & Pharmaceutical (TPE:1701) Share Price Is Up 22% And Shareholders Are Holding On

Dec 16
The China Chemical & Pharmaceutical (TPE:1701) Share Price Is Up 22% And Shareholders Are Holding On

China Chemical & Pharmaceutical Co., Ltd. (TPE:1701) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Nov 26
China Chemical & Pharmaceutical Co., Ltd. (TPE:1701) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Opbrengsten en kosten

Hoe Cenra geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

TWSE:1701 Opbrengsten, kosten en inkomsten (TWD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 248,8713552,449485
31 Mar 248,7623282,440472
31 Dec 238,5753222,416486
30 Sep 238,6193172,513463
30 Jun 238,5993872,474470
31 Mar 238,5724892,348457
31 Dec 228,4574782,283436
30 Sep 228,1475262,076417
30 Jun 227,9815282,016400
31 Mar 227,9364772,070399
31 Dec 217,9495182,062391
30 Sep 218,1024592,222402
30 Jun 218,2114482,216429
31 Mar 218,0885742,124436
31 Dec 208,1815572,134444
30 Sep 208,0615312,040476
30 Jun 208,0065122,057448
31 Mar 208,0754122,121456
31 Dec 197,9703852,150452
30 Sep 197,6303602,143426
30 Jun 197,6693682,161438
31 Mar 197,5473432,135422
31 Dec 187,5803702,125403
30 Sep 187,5623742,042381
30 Jun 187,0833721,787364
31 Mar 186,7143261,571347
31 Dec 176,2453111,301344
30 Sep 175,9882931,160340
30 Jun 175,8482571,130330
31 Mar 175,8223051,103324
31 Dec 165,7813131,077325
30 Sep 165,7853111,050319
30 Jun 165,7713621,046323
31 Mar 165,7173521,032320
31 Dec 155,6283541,040327
30 Sep 155,5684501,043346
30 Jun 155,4713951,017348
31 Mar 155,3503841,009358
31 Dec 145,297348982362
30 Sep 145,257253974363
30 Jun 145,274260976364
31 Mar 145,271266983358
31 Dec 135,174240977355
30 Sep 135,1252561,014338

Kwaliteitswinsten: 1701 has high quality earnings.

Groeiende winstmarge: 1701's current net profit margins (4%) are lower than last year (4.5%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: 1701's earnings have declined by 3.3% per year over the past 5 years.

Versnelling van de groei: 1701's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Winst versus industrie: 1701 had negative earnings growth (-8.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).

Rendement op eigen vermogen

Hoge ROE: 1701's Return on Equity (4.8%) is considered low.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y